GlobeNewswire·Nov 10, 2026, 1:00 AM ET

Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®

Valneva reported positive five-year antibody persistence data for the single-dose chikungunya vaccine IXCHIQ® on November 10, 2026.
94% of the 221 evaluable healthy adults maintained neutralizing antibody titers above the seroresponse threshold five years post-vaccination.
Antibody persistence in adults aged 65 years & older was comparable to that observed in adults aged 18 to 64 years.
Trial VLA1553-303 received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) & the European Union's Horizon Europe program.
Participants in the trial will continue to be followed for up to ten years to characterize long-term immune response durability.
A Pilot Vaccination Strategy (PVS) in Brazil vaccinated nearly 80,000 adults aged 18 to 59 years between February & October 2026.
The PVS serves as the foundation for ongoing post-marketing studies expected to generate effectiveness & safety data.
Chikungunya is a mosquito-borne viral disease identified in over 110 countries, causing significant medical & economic burdens.
Valneva is developing additional vaccine candidates, including a Lyme disease vaccine partnered with Pfizer & a Shigella vaccine.